drugset
Drugs / BAT2506
last change Oct 2023 re-read 9 days ago

BAT2506

also known as Simponi(EU-licensed)
Developed for
psoriatic arthritis
Investigated by
Bio-Thera Solutions · The First Hospital of Jilin University

Trials 3

today NCT05332730 · Ph 1 NCT05046431 · Ph 3 NCT04152759 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials · 1 met primary
Phase 1 NCT05332730 Aug 2022 → Jun 2023 psoriatic arthritis Bio-Thera Solutions Completed No outcome recorded
Phase 1 NCT04152759 Sep 2019 → Dec 2020 psoriatic arthritis Bio-Thera Solutions Completed Met primary
Phase 31 trial · 1 met primary
Phase 3 NCT05046431 May 2021 → Oct 2023 psoriatic arthritis Bio-Thera Solutions Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BAT2506 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05046431 ↗
2

NCT05332730 ↗

NCT04152759 ↗
Known as Simponi(EU-licensed) “Drug: BAT2506 injection Other Names: Simponi(EU-licensed)” NCT04152759 ↗
Route Subcutaneous “single subcutaneous administration of 50mg BAT2506 Injection or Simponi® (EU-licensed ).” NCT04152759 ↗